Disfruta de todo el potencial de biblioEteca entrando con tu usuario...
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ?2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Según nuestros usuarios
Etiquetas de otros usuarios
Así han etiquetado este libro más usuarios